Document And Entity Information
Document And Entity Information - shares | 6 Months Ended | |
Jul. 31, 2017 | Sep. 14, 2017 | |
Document Information [Line Items] | ||
Entity Registrant Name | Comarco Inc | |
Entity Central Index Key | 22,252 | |
Trading Symbol | cmro | |
Current Fiscal Year End Date | --01-31 | |
Entity Filer Category | Smaller Reporting Company | |
Entity Current Reporting Status | Yes | |
Entity Voluntary Filers | No | |
Entity Well-known Seasoned Issuer | No | |
Entity Common Stock, Shares Outstanding (in shares) | 14,614,165 | |
Document Type | 10-Q | |
Document Period End Date | Jul. 31, 2017 | |
Document Fiscal Year Focus | 2,018 | |
Document Fiscal Period Focus | Q2 | |
Amendment Flag | false |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands | Jul. 31, 2017 | Jan. 31, 2017 |
ASSETS | ||
Cash and cash equivalents | $ 101 | $ 618 |
Other current assets | 32 | 14 |
Total current assets | 133 | 632 |
Total assets | 133 | 632 |
LIABILITIES AND STOCKHOLDERS' (DEFICIT) EQUITY | ||
Accounts payable | 2 | 6 |
Accrued liabilities | 300 | 384 |
Income taxes payable | 5 | |
Total current liabilities | 302 | 395 |
Total liabilities | 302 | 395 |
Commitments and Contingencies (Note 7) | ||
Stockholders' Equity: | ||
Preferred stock, no par value, 10,000,000 shares authorized; no shares issued or outstanding | 0 | 0 |
Common stock, $0.10 par value, 50,625,000 shares authorized; 14,614,165 shares issued and outstanding at July 31, 2017 and January 31, 2017 | 1,461 | 1,461 |
Additional paid-in capital | 18,422 | 18,410 |
Accumulated deficit | (20,052) | (19,634) |
Total stockholders' (deficit) equity | (169) | 237 |
Total liabilities and stockholders' (deficit) equity | $ 133 | $ 632 |
Condensed Consolidated Balance3
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares | Jul. 31, 2017 | Jan. 31, 2017 |
Preferred stock, par value (in dollars per share) | $ 0 | $ 0 |
Preferred stock, shares authorized (in shares) | 10,000,000 | 10,000,000 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.10 | $ 0.10 |
Common stock, shares authorized (in shares) | 50,625,000 | 50,625,000 |
Common stock, shares issued (in shares) | 14,614,165 | 14,614,165 |
Common stock, shares outstanding (in shares) | 14,614,165 | 14,614,165 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jul. 31, 2017 | Jul. 31, 2016 | Jul. 31, 2017 | Jul. 31, 2016 | |
Royalty income | $ 6 | $ 6 | ||
Cost of revenue | (472) | (472) | ||
Gross profit | 6 | 472 | 6 | 472 |
Selling, general and administrative expenses | 202 | 360 | 424 | 724 |
202 | 360 | 424 | 724 | |
Operating loss | (196) | 112 | (418) | (252) |
Other income, net | 16 | 1,704 | ||
(Loss) income from operations before income taxes | (196) | 128 | (418) | 1,452 |
Income tax expense | ||||
Net (loss) income | $ (196) | $ 128 | $ (418) | $ 1,452 |
(Loss) income per basic share: (in dollars per share) | $ (0.01) | $ 0.01 | $ (0.03) | $ 0.10 |
(Loss) income per diluted share: (in dollars per share) | $ (0.01) | $ 0.01 | $ (0.03) | $ 0.10 |
Weighted-average shares outstanding basic and diluted: (in shares) | 14,615 | 14,644 | 14,615 | 14,644 |
Condensed Consolidated Stateme5
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 6 Months Ended | |
Jul. 31, 2017 | Jul. 31, 2016 | |
CASH FLOWS FROM OPERATING ACTIVITIES: | ||
Net (loss) income | $ (418) | $ 1,452 |
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities: | ||
Depreciation and amortization | 2 | |
Stock-based compensation expense | 12 | 18 |
Changes in operating assets and liabilities | ||
Accounts receivable due from suppliers | 122 | |
Other assets | (18) | (22) |
Accounts payable | (4) | (756) |
Accrued liabilities | (84) | (362) |
Income taxes payable | (5) | |
Net cash (used in) provided by operating activities | (517) | 454 |
Net (decrease) increase in cash and cash equivalents | (517) | 454 |
Cash and cash equivalents, beginning of period | 618 | 680 |
Cash and cash equivalents, end of period | 101 | 1,134 |
Supplementary disclosures of cash flow information: | ||
Cash paid for income taxes, net of refunds | $ 6 | $ 40 |
Note 1 - Organization
Note 1 - Organization | 6 Months Ended |
Jul. 31, 2017 | |
Notes to Financial Statements | |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | 1. Organization Comarco, Inc. was incorporated in California in 1960 1971, September 1993. |
Note 2 - Current Developments,
Note 2 - Current Developments, Future Operations, Liquidity and Capital Resources | 6 Months Ended |
Jul. 31, 2017 | |
Notes to Financial Statements | |
Going Concern [Text Block] | 2. Current Developments, Future Operations, Liquidity and Capital Resources The unaudited consolidated financial statements have been prepared assuming that we will continue to operate as a going concern. As of July 31, 2017, $169,000. no 8 September 12, 2017, 7,000,000 $700,000 twelve Our business is currently focused on potentially realizing value from our ongoing or future IP enforcement actions and other litigation as well as further exploring opportunities to expand, protect, and monetize our patent portfolio, including through the potential sale or licensing of some or all our patent portfolio. On February 3, 2015, 20 September 2015, No. 8,492,933 B2 “933 February 22, 2017, 12 8 12 may no On February 13, 2015, inter partes inter partes We have and will continue to analyze alternatives to build and/or preserve value for our stakeholders, including, but not no We believe that our patent portfolio covering key technical aspects of our products could potentially generate a future revenue stream based upon royalties paid to us by others for the use of some or all of our patented technology in third may may not no |
Note 3 - Summary of Significant
Note 3 - Summary of Significant Accounting Policies | 6 Months Ended |
Jul. 31, 2017 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | 3. Summary of Significant Accounting Policies The summary of our significant accounting policies presented below is designed to assist the reader in understanding our consolidated financial statements. Such financial statements and related notes are the representations of our management, who are responsible for their integrity and objectivity. Basis of Presentation The accompanying condensed consolidated balance sheet as of January 31, 2017, three six July 31, 2017 10 8 X. not not 10 January 31, 2017 “2017 10 May 1, 2017. 3 2017 10 three six July 31, 2017 not January 31, 2018. Reclassification Certain prior year and prior period amounts have been reclassified for consistency with the current period presentation. These reclassifications had no Principles of Consolidation The unaudited interim consolidated financial statements of the Company include the accounts of Comarco, Inc. and CWT, its wholly owned subsidiary. All material intercompany balances, transactions, and profits and losses have been eliminated. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenue and expenses during the periods reported. Actual results could materially differ from those estimates. Certain accounting principles require subjective and complex judgments to be used in the preparation of financial statements. Accordingly, a different financial presentation could result depending on the judgments, estimates, or assumptions that are used. Such estimates and assumptions include, but are not Cash and Cash Equivalents All highly liquid investments with original maturity dates of three Fair Value of Financial Instruments Our financial instruments include cash and cash equivalents, accounts payable and accrued liabilities. The carrying amount of cash and cash equivalents, accounts payable, and accrued liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments. Legal expense classification All legal expenses, including expenses related to our intellectual property litigation, maintenance of our patent portfolio, public company legal expense, and all other litigation expense, are included in selling, general, and administrative expenses in the accompanying condensed consolidated statement of operations. Income tax expense Significant management judgment is required in determining our provision for income taxes, our deferred tax assets and liabilities and any required valuation allowance. We continue to maintain a full valuation allowance on the entire deferred tax asset balance. This valuation allowance was established based on management’s overall assessment of risks and uncertainties related to our future ability to realize, and hence, utilize certain deferred tax assets, primarily consisting of net operating loss carry forwards and temporary differences. Due to the current and prior years’ operating losses, the adjusted net deferred tax assets remained fully reserved as of July 31, 2017. Net (Loss) Income Per Common Share Basic net (loss) income per share is computed by dividing net (loss) income by the weighted average number of common shares outstanding during the period excluding the dilutive effect of potential common stock, which for us consists solely of stock awards. Diluted earnings per share reflects the dilution that would result from the exercise of all dilutive stock awards outstanding during the period. The effect of such potential common stock is computed using the treasury stock method (see Note 5 Recent Accounting Pronouncements In February 2016, 2016 02, 842 2016 02” 2016 02 December 15, 2018, 2016 02 first 2020. not not In May 2014, 2014 09, 606 2014 09 five 2014 09 April 1, 2015, one December 15, 2018. 2014 09 first 2020. not not We do not not Subsequent Events Management has evaluated events subsequent to July 31, 2017 may |
Note 4 - Stock-based Compensati
Note 4 - Stock-based Compensation | 6 Months Ended |
Jul. 31, 2017 | |
Notes to Financial Statements | |
Disclosure of Compensation Related Costs, Share-based Payments [Text Block] | 4. Stock-Based Compensation We grant stock awards for a fixed number of shares to employees, consultants’, and directors pursuant to our shareholder-approved equity incentive plans. We account for stock-based compensation using the modified prospective method, which requires measurement of compensation cost for all stock awards at fair value on date of grant and recognition of compensation over the service period for awards expected to vest. The fair value of stock options is determined using the Black-Scholes valuation model for options with ratable term vesting. The valuation model requires the input of subjective assumptions. These assumptions include estimating the length of time optionees will retain their vested stock options before exercising them (the “expected term”), the estimated volatility of our common stock price over the expected term, and the number of awards that will ultimately not may The compensation expense recognized is summarized in the table below (in thousands except per share amounts): The total compensation cost related to unvested awards not $6,750 third 2018. During the three six July 31, 2017 2016, no no Three Months Ended Six Months Ended July 31, July 31, 2017 2016 2017 2016 Stock-based compensation expense $ 7 $ 5 $ 12 $ 18 Impact on basic and diluted earnings per share $ 0.00 $ 0.00 $ 0.00 $ 0.00 Transactions and other information related to stock options granted under these plans for the three six July31, 2017 Outstanding Options Weighted-Ave. Number of Exercise Shares Price Balance, January 31, 2017 1,100,000 $ 0.37 Options granted - - Options canceled or expired - - Options exercised - - Balance, July 31, 2017 1,100,000 $ 0.37 Stock Options Exercisable at July 31, 2017 760,000 $ 0.44 As of July 31, 2017, $0, $0.03 July 31, 2017. July 31, 2017: Awards Outstanding Options Exercisable Weighted-Ave. Remaining Weighted-Ave. Weighted-Ave. Range of Number Contractural Exercise/Grant Number Exercise Exercise / Grant Prices Outstanding Life Price Exercisable Price $0.09 300,000 9.25 $ 0.09 - $ 0.09 $0.14 - $ 0.16 300,000 7.88 $ 0.15 300,000 $ 0.15 $0.40 385,000 5.01 $ 0.40 385,000 $ 0.40 $1.09 100,000 1.28 $ 1.00 60,000 $ 1.09 $4.53 15,000 0.58 $ 4.53 15,000 $ 4.53 1,100,000 760,000 Shares available under the plans for future grants at July 31, 2017 323,535. |
Note 5 - Net (Loss) Income Per
Note 5 - Net (Loss) Income Per Share | 6 Months Ended |
Jul. 31, 2017 | |
Notes to Financial Statements | |
Earnings Per Share [Text Block] | 5. Net (Loss) Income Per Share We calculate basic (loss) income per share by dividing net (loss) income by the weighted-average number of common shares outstanding during the reporting period. Diluted (loss) income per share reflects the effects of dilutive potential common shares. Because we incurred a net loss for the three six July 31, 2017, three six July 31, 2016, Potential common shares of 3,190,000 3,073,736 three six July 31, 2017 2016, |
Note 6 - Accrued Liabilities
Note 6 - Accrued Liabilities | 6 Months Ended |
Jul. 31, 2017 | |
Notes to Financial Statements | |
Accounts Payable and Accrued Liabilities Disclosure [Text Block] | 6 . Accrued Liabilities Accrued liabilities consist of the following as of July 31, 2017 January 31, 2017 ( As of July 31, As of January 31, 2017 2017 Accrued legal and professional fees $ 124 $ 94 Accrued payroll and related expesnses 10 21 Accrued consulting - 80 Other 166 189 $ 300 $ 384 |
Note 7 - Commitments and Contin
Note 7 - Commitments and Contingencies | 6 Months Ended |
Jul. 31, 2017 | |
Notes to Financial Statements | |
Commitments and Contingencies Disclosure [Text Block] | 7 . Commitments and Contingencies Executive Severance Commitments We have a severance compensation agreement with our Chief Executive Officer, Thomas Lanni. This agreement requires us to pay Mr. Lanni, in the event of a termination of employment following a change of control of the Company or certain other circumstances, the amount of his then current annual base salary and the amount of any bonus amount he would have achieved for the year in which the termination occurs plus the acceleration of unvested options. We have not As of April 1, 2017, $4,500 $3,000 $1,500 $1,250 $0 $1,250 10 10 $3.0 Executive and Board of Directors Compensation On November 2, 2013, July 31, 2017, no not Legal Contingencies On February 13, 2015, On February 3, 2015, 20 September 2015, inter partes 933 February 22, 2017, 12 8 12 may no . In addition to the pending matters described above, we are, from time to time, involved in various legal proceedings incidental to the conduct of our business. We are unable to predict the ultimate outcome of these matters. |
Note 8 - Subsequent Events
Note 8 - Subsequent Events | 6 Months Ended |
Jul. 31, 2017 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | 8 . Subsequent Events On September 11, 2017, two 5,000,000 2,000,000 $0.10 September 12, 2017, $700,000. no 18,026,500 7,210,600 eight $0.05 February 22, 2017 ( PTAB Decision 933 September 6, 2017 $700,000. |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 6 Months Ended |
Jul. 31, 2017 | |
Accounting Policies [Abstract] | |
Basis of Accounting, Policy [Policy Text Block] | Basis of Presentation The accompanying condensed consolidated balance sheet as of January 31, 2017, three six July 31, 2017 10 8 X. not not 10 January 31, 2017 “2017 10 May 1, 2017. 3 2017 10 three six July 31, 2017 not January 31, 2018. |
Reclassification, Policy [Policy Text Block] | Reclassification Certain prior year and prior period amounts have been reclassified for consistency with the current period presentation. These reclassifications had no |
Consolidation, Policy [Policy Text Block] | Principles of Consolidation The unaudited interim consolidated financial statements of the Company include the accounts of Comarco, Inc. and CWT, its wholly owned subsidiary. All material intercompany balances, transactions, and profits and losses have been eliminated. |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenue and expenses during the periods reported. Actual results could materially differ from those estimates. Certain accounting principles require subjective and complex judgments to be used in the preparation of financial statements. Accordingly, a different financial presentation could result depending on the judgments, estimates, or assumptions that are used. Such estimates and assumptions include, but are not |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash and Cash Equivalents All highly liquid investments with original maturity dates of three |
Fair Value of Financial Instruments, Policy [Policy Text Block] | Fair Value of Financial Instruments Our financial instruments include cash and cash equivalents, accounts payable and accrued liabilities. The carrying amount of cash and cash equivalents, accounts payable, and accrued liabilities are considered to be representative of their respective fair values because of the short-term nature of those instruments. |
Selling, General and Administrative Expenses, Policy [Policy Text Block] | Legal expense classification All legal expenses incurred related to our intellectual property, including associated litigation expense and maintenance of our patent portfolio, public company legal expense, and all other litigation expense are included in selling, general, and administrative expenses in the accompanying condensed consolidated statement of operations. |
Income Tax, Policy [Policy Text Block] | Income tax expense Significant management judgment is required in determining our provision for income taxes, our deferred tax assets and liabilities and any required valuation allowance. We continue to maintain a full valuation allowance on the entire deferred tax asset balance. This valuation allowance was established based on management’s overall assessment of risks and uncertainties related to our future ability to realize, and hence, utilize certain deferred tax assets, primarily consisting of net operating loss carry forwards and temporary differences. Due to the current and prior years’ operating losses, the adjusted net deferred tax assets remained fully reserved as of July 31, 2017. |
Earnings Per Share, Policy [Policy Text Block] | Net (Loss) Income Per Common Share Basic net (loss) income per share is computed by dividing net (loss) income by the weighted average number of common shares outstanding during the period excluding the dilutive effect of potential common stock, which for us consists solely of stock awards. Diluted earnings per share reflects the dilution that would result from the exercise of all dilutive stock awards outstanding during the period. The effect of such potential common stock is computed using the treasury stock method (see Note 5 |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent Accounting Pronouncements In February 2016, 2016 02, 842 2016 02” 2016 02 December 15, 2018, 2016 02 first 2020. not not In May 2014, 2014 09, 606 2014 09 five 2014 09 April 1, 2015, one December 15, 2018. 2014 09 first 2020. not not We do not not |
Subsequent Events, Policy [Policy Text Block] | Subsequent Events Management has evaluated events subsequent to July 31, 2017 may |
Note 4 - Stock-based Compensa15
Note 4 - Stock-based Compensation (Tables) | 6 Months Ended |
Jul. 31, 2017 | |
Notes Tables | |
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block] | Three Months Ended Six Months Ended July 31, July 31, 2017 2016 2017 2016 Stock-based compensation expense $ 7 $ 5 $ 12 $ 18 Impact on basic and diluted earnings per share $ 0.00 $ 0.00 $ 0.00 $ 0.00 |
Share-based Compensation, Stock Options, Activity [Table Text Block] | Outstanding Options Weighted-Ave. Number of Exercise Shares Price Balance, January 31, 2017 1,100,000 $ 0.37 Options granted - - Options canceled or expired - - Options exercised - - Balance, July 31, 2017 1,100,000 $ 0.37 Stock Options Exercisable at July 31, 2017 760,000 $ 0.44 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding and Exercisable [Table Text Block] | Awards Outstanding Options Exercisable Weighted-Ave. Remaining Weighted-Ave. Weighted-Ave. Range of Number Contractural Exercise/Grant Number Exercise Exercise / Grant Prices Outstanding Life Price Exercisable Price $0.09 300,000 9.25 $ 0.09 - $ 0.09 $0.14 - $ 0.16 300,000 7.88 $ 0.15 300,000 $ 0.15 $0.40 385,000 5.01 $ 0.40 385,000 $ 0.40 $1.09 100,000 1.28 $ 1.00 60,000 $ 1.09 $4.53 15,000 0.58 $ 4.53 15,000 $ 4.53 1,100,000 760,000 |
Note 6 - Accrued Liabilities (T
Note 6 - Accrued Liabilities (Tables) | 6 Months Ended |
Jul. 31, 2017 | |
Notes Tables | |
Schedule of Accrued Liabilities [Table Text Block] | As of July 31, As of January 31, 2017 2017 Accrued legal and professional fees $ 124 $ 94 Accrued payroll and related expesnses 10 21 Accrued consulting - 80 Other 166 189 $ 300 $ 384 |
Note 2 - Current Developments17
Note 2 - Current Developments, Future Operations, Liquidity and Capital Resources (Details Textual) - USD ($) | Sep. 12, 2017 | Jul. 31, 2017 |
Working Capital | $ (169,000) | |
Series A Contingent Convertible Preferred Stock [Member] | Subsequent Event [Member] | ||
Stock Issued During Period, Shares, New Issues | 7,000,000 | |
Proceeds from Issuance of Preferred Stock and Preference Stock | $ 700,000 |
Note 4 - Stock-based Compensa18
Note 4 - Stock-based Compensation (Details Textual) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jul. 31, 2017 | Jul. 31, 2016 | Jul. 31, 2017 | Jul. 31, 2016 | |
Share Price | $ 0.03 | $ 0.03 | ||
Common Stock, Capital Shares Reserved for Future Issuance | 323,535 | 323,535 | ||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized | $ 6,750 | $ 6,750 | ||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 0 | 0 | 0 | 0 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value | $ 0 | $ 0 | ||
Restricted Stock [Member] | ||||
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | 0 | 0 | 0 | 0 |
Note 4 - Stock-based Compensa19
Note 4 - Stock-based Compensation - Share-based Compensation Expense (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jul. 31, 2017 | Jul. 31, 2016 | Jul. 31, 2017 | Jul. 31, 2016 | |
Stock-based compensation expense | $ 7 | $ 5 | $ 12 | $ 18 |
Impact on basic and diluted earnings per share (in dollars per share) | $ 0 | $ 0 | $ 0 | $ 0 |
Note 4 - Stock-based Compensa20
Note 4 - Stock-based Compensation - Stock Options Activity (Details) - $ / shares | 3 Months Ended | 6 Months Ended | ||
Jul. 31, 2017 | Jul. 31, 2016 | Jul. 31, 2017 | Jul. 31, 2016 | |
Balance, stock options (in shares) | 1,100,000 | |||
Balance, stock options, weighted-average exercise price (in dollars per share) | $ 0.37 | |||
Options granted (in shares) | 0 | 0 | 0 | 0 |
Options granted, weighted-average exercise price (in dollars per share) | ||||
Options canceled or expired (in shares) | ||||
Options canceled or expired, weighted-average exercise price (in dollars per share) | ||||
Balance, stock options, weighted-average exercise price (in dollars per share) | $ 0.37 | $ 0.37 | ||
Stock options exercisable (in shares) | 760,000 | 760,000 | ||
Stock options exercisable, weighted-average exercise price (in dollars per share) | $ 0.44 | $ 0.44 | ||
Options exercised (in shares) | ||||
Options exercised (in dollars per share) | ||||
Balance, stock options (in shares) | 1,100,000 | 1,100,000 |
Note 4 - Stock-based Compensa21
Note 4 - Stock-based Compensation - Stock Awards Outstanding (Details) | 6 Months Ended |
Jul. 31, 2017$ / sharesshares | |
Number Outstanding (in shares) | shares | 1,100,000 |
Exercisable Number Exercisable (in shares) | shares | 760,000 |
Range 1 [Member] | |
Upper Range of Exercise/Grant Prices (in dollars per share) | |
Number Outstanding (in shares) | shares | 300,000 |
Weighted-Ave. Remaining Contractual Life (Year) | 9 years 91 days |
Weighted-Ave. Exercise/Grant Price (in dollars per share) | $ 0.09 |
Exercisable Number Exercisable (in shares) | shares | |
Exercisable Weighted-Ave. Exercise Price (in dollars per share) | $ 0.09 |
Lower Range of Exercise/Grant Prices (in dollars per share) | 0.09 |
Range 2 [Member] | |
Upper Range of Exercise/Grant Prices (in dollars per share) | $ 0.16 |
Number Outstanding (in shares) | shares | 300,000 |
Weighted-Ave. Remaining Contractual Life (Year) | 7 years 321 days |
Weighted-Ave. Exercise/Grant Price (in dollars per share) | $ 0.15 |
Exercisable Number Exercisable (in shares) | shares | 300,000 |
Exercisable Weighted-Ave. Exercise Price (in dollars per share) | $ 0.15 |
Lower Range of Exercise/Grant Prices (in dollars per share) | 0.14 |
Range 3 [Member] | |
Upper Range of Exercise/Grant Prices (in dollars per share) | |
Number Outstanding (in shares) | shares | 385,000 |
Weighted-Ave. Remaining Contractual Life (Year) | 5 years 3 days |
Weighted-Ave. Exercise/Grant Price (in dollars per share) | $ 0.40 |
Exercisable Number Exercisable (in shares) | shares | 385,000 |
Exercisable Weighted-Ave. Exercise Price (in dollars per share) | $ 0.40 |
Lower Range of Exercise/Grant Prices (in dollars per share) | 0.40 |
Range 4 [Member] | |
Upper Range of Exercise/Grant Prices (in dollars per share) | |
Number Outstanding (in shares) | shares | 100,000 |
Weighted-Ave. Remaining Contractual Life (Year) | 1 year 102 days |
Weighted-Ave. Exercise/Grant Price (in dollars per share) | $ 1 |
Exercisable Number Exercisable (in shares) | shares | 60,000 |
Exercisable Weighted-Ave. Exercise Price (in dollars per share) | $ 1.09 |
Lower Range of Exercise/Grant Prices (in dollars per share) | 1.09 |
Range 5 [Member] | |
Upper Range of Exercise/Grant Prices (in dollars per share) | |
Number Outstanding (in shares) | shares | 15,000 |
Weighted-Ave. Remaining Contractual Life (Year) | 211 days |
Weighted-Ave. Exercise/Grant Price (in dollars per share) | $ 4.53 |
Exercisable Number Exercisable (in shares) | shares | 15,000 |
Exercisable Weighted-Ave. Exercise Price (in dollars per share) | $ 4.53 |
Lower Range of Exercise/Grant Prices (in dollars per share) | $ 4.53 |
Note 5 - Net (Loss) Income Pe22
Note 5 - Net (Loss) Income Per Share (Details Textual) - shares | 3 Months Ended | 6 Months Ended | ||
Jul. 31, 2017 | Jul. 31, 2016 | Jul. 31, 2017 | Jul. 31, 2016 | |
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 3,190,000 | 3,073,736 | 3,190,000 | 3,073,736 |
Note 6 - Accrued Liabilities -
Note 6 - Accrued Liabilities - Accrued Liabilities (Details) - USD ($) $ in Thousands | Jul. 31, 2017 | Jan. 31, 2017 |
Accrued legal and professional fees | $ 124 | $ 94 |
Accrued payroll and related expesnses | 10 | 21 |
Accrued consulting | 80 | |
Other | 166 | 189 |
$ 300 | $ 384 |
Note 7 - Commitments and Cont24
Note 7 - Commitments and Contingencies (Details Textual) - USD ($) | Apr. 01, 2017 | Mar. 31, 2017 | Jul. 31, 2017 |
Deferred Compensation, Cash Net of Liabilities, Maximum | $ 3,000,000 | ||
Deferred Compensation Liability, Current and Noncurrent | $ 0 | ||
Board of Directors Chairman [Member] | |||
Monthly Deferred Compensation | 1,500 | ||
Monthly Cash Compensation | 3,000 | $ 4,500 | |
Director [Member] | |||
Monthly Deferred Compensation | 1,250 | ||
Monthly Cash Compensation | $ 0 | $ 1,250 |
Note 8 - Subsequent Events (Det
Note 8 - Subsequent Events (Details Textual) - USD ($) | Feb. 22, 2018 | Sep. 12, 2017 | Feb. 22, 2018 | Jul. 31, 2017 |
Share Price | $ 0.03 | |||
Scenario, Forecast [Member] | ||||
Warrant Term | 8 years | |||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.05 | $ 0.05 | ||
Warrants Issuance Trigger, Funding Threshold | $ 700,000 | |||
Broadwood Partners, L.P. [Member] | Scenario, Forecast [Member] | ||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 18,026,500 | 18,026,500 | ||
Elkhorn Partners Limited Partnership [Member] | Scenario, Forecast [Member] | ||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 7,210,600 | 7,210,600 | ||
Series A Contingent Convertible Preferred Stock [Member] | Subsequent Event [Member] | ||||
Stock Issued During Period, Shares, New Issues | 7,000,000 | |||
Share Price | $ 0.10 | |||
Proceeds from Issuance of Preferred Stock and Preference Stock | $ 700,000 | |||
Series A Contingent Convertible Preferred Stock [Member] | Subsequent Event [Member] | Broadwood Partners, L.P. [Member] | ||||
Stock Issued During Period, Shares, New Issues | 5,000,000 | |||
Series A Contingent Convertible Preferred Stock [Member] | Subsequent Event [Member] | Elkhorn Partners Limited Partnership [Member] | ||||
Stock Issued During Period, Shares, New Issues | 2,000,000 |